HUYA Bioscience International Strengthens Business Development in China

Appoints Shawn Xiaojun Mu as Vice President of BD based in China

San Diego, CA, USA – October 8, 2015 –HUYA Bioscience International (HUYA) today announced an expansion of its Senior Management Team, with the appointment of Shawn Xiaojun Mu Ph.D., as Vice President of Business Development, China.

Dr. Mu has over 20 years of experience in healthcare investment including startups, global pharmaceutical business, and academic research in the field of life sciences. He spent more than ten years in the U.S. with Aventis Pharma and KV Pharmaceutical, where his main responsibilities were in strategic planning and market research. Prior to joining HUYA, Dr. Mu founded Pivot PharmTech, a drug development company in Shanghai, and was a partner for several investment firms focused on the healthcare industry.

“Dr. Shawn Mu joins the HUYA team at a perfect time as our China and global business is advancing to an exciting and pivotal stage,” said Clement Gingras, HUYA’s CTO and COO Asia. “Shawn’s extensive experience in pharmaceutical business and research will help ensure sustainable progress in HUYA’s strategic global development of innovative drugs originating from China.”

Most recently, Dr. Mu was a founding partner of Excess Alliance Consulting in Shanghai, helping pharmaceutical and medical device companies to develop business plans and financing strategies. Prior to that, he was a venture partner at Tririver Capital, where he managed a $25 million biomedical angel fund and guided the firm’s overall investment strategy in the healthcare area.

Educated in both China and the U.S., Dr. Mu received his Ph.D. in Neurobiology from the University of Kentucky, and MBA from Thunderbird School of Global Management at Arizona State University.

About HUYA Bioscience International
HUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan and eight strategic locations across China, with joint headquarters in San Diego and Shanghai. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. Earlier this year, HUYA was named the winner of a Stevie® Award in the Health Products & Services and Pharmaceuticals category in the Asia-Pacific Stevie Awards.

Contact Details:
Yiota Merianos
HUYA Corporate Communications